Luis, Tiago C. http://orcid.org/0000-0002-6305-1257
Barkas, Nikolaos
Carrelha, Joana
Giustacchini, Alice http://orcid.org/0000-0002-8733-8594
Mazzi, Stefania
Norfo, Ruggiero
Wu, Bishan
Aliouat, Affaf
Guerrero, Jose A. http://orcid.org/0000-0003-4307-6948
Rodriguez-Meira, Alba
Bouriez-Jones, Tiphaine
Macaulay, Iain C. http://orcid.org/0000-0002-6761-757X
Jasztal, Maria
Zhu, Guangheng
Ni, Heyu http://orcid.org/0000-0002-7621-2945
Robson, Matthew J. http://orcid.org/0000-0002-3277-3062
Blakely, Randy D. http://orcid.org/0000-0002-2182-6966
Mead, Adam J. http://orcid.org/0000-0001-8522-1002
Nerlov, Claus http://orcid.org/0000-0002-0544-735X
Ghevaert, Cedric
Jacobsen, Sten Eirik W. http://orcid.org/0000-0002-1362-3659
Funding for this research was provided by:
RCUK | Medical Research Council (MC_UU_12009)
Kay Kendall Leukaemia Fund (KKL832)
Article History
Received: 31 March 2022
Accepted: 11 September 2023
First Online: 28 September 2023
Competing interests
: H.N. is the President and CEO, and G.Z. is an employee of CCOA Therapeutics Inc. Both authors are inventors of the monoclonal antibody NIT E (Canada patent number: 2, 689, 726; US patent number: US8, 323, 652 B2; and European patent number: 2186829). All other authors declare no competing interests.